Yüklüyor......
HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status
PURPOSE: Immunotherapy with antibodies against B7/CD28 family members, including PD-1, PD-L1, and CTLA-4 has shifted the treatment paradigm for non-small-cell lung carcinoma (NSCLC) with improved clinical outcome. HHLA2 is a newly discovered member of the family. By regulating T-cell function, HHLA2...
Kaydedildi:
| Yayımlandı: | Clin Cancer Res |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5290088/ https://ncbi.nlm.nih.gov/pubmed/27553831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-3071 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|